Portfolio News

 

   
April 15, 2016
SV Life Sciences and Health Enterprise Partners Announce Formation of Jet Health
Accomplished healthcare executive Jim Glynn to lead home healthcare platform For Immediate Release Irvine, CA, April 15, 2016 – SV Life Sciences Advisers (“SVLS”) and Health Enterprise Partners (“HEP”) announced today that they have partnered with experienced healthcare services executive Jim Glynn to form Jet Health, Inc. (“Jet Health”).

Read more

Team - James Garvey
May 2014
Urgent Team Holdings
SV Life Sciences Fund V invested in Urgent Team Holdings (UTH) as part of a $10.2m series B financing round. UTH own and operate a regional network of urgent care facilities in the Southern United States.   ...

Read more

Team - Tom Flynn, Eugene Hill
January 2014
Maestro Healthcare Technology Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in Maestro Healthcare, Technology-enabled healthcare service company that sells defined contribution plans to employers via private exchange as part of a seed loan financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
May 2013
Maestro Healthcare Technology Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in Maestro Healthcare, Technology-enabled healthcare service company that sells defined contribution plans to employers via private exchange as part of a $1m financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
May 2013
Autifony Therapeutics Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in Maestro Healthcare, Technology-enabled healthcare service company that sells defined contribution plans to employers via private exchange as part of a $1m financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
April 2013
WellNow Urgent Care Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in WellNow Urgent Care, an urgent care company focused on treating patients. Clinics offer you the convenience and expertise to treat everything that is non-life or limb threatening illness or injury as part of a $25m series A financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
February 2013
CoreLab (Medifacts) - Exit
SV Life Sciences Fund III notes that Bioclinica (NASDAQ: BIOC) acquired CoreLab for $60M cash upfront plus cash less debt, working capital adjustment, transactions expenses, management transaction bonus and $6M Escrow-net of $45.65M plus up to $12M Earnout based upon delta between 2013 and 2014.   ...

Read more

Team - Eugene Hill
December 2012
WellNow Urgent Care Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in WellNow Urgent Care, an urgent care company focused on treating patients. Clinics offer you the convenience and expertise to treat everything that is non-life or limb threatening illness or injury as part of a $4.4m financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
October 2012
Health Essentials
SV Life Sciences notes the SV Life Science Fund V invested in Health Essentials, a leading provider of post-acute care management services as part of a $34m financing round.  ...

Read more

Team - Tom Flynn, Eugene Hill
September 2012
Nordic Consulting Partners Investment
SV Life Sciences notes that SV Life Science Fund V invested in Nordic Consulting Partners, a leading Healthcare IT (HIT) consulting firm focused exclusively on the implementation of Epic systems at healthcare providers as part of a $22m financing round.  ...

Read more

Team - Tom Flynn, Eugene Hill
September 2012
WellNow Urgent Care Investment
SV Life Sciences Advisers notes that SV Life Science Fund V invested in WellNow Urgent Care, an urgent care company focused on treating patients. Clinics offer you the convenience and expertise to treat everything that is non-life or limb threatening illness or injury as part of a $5m financing round. ...

Read more

Team - Tom Flynn, Eugene Hill
July 2012
U.S. Renal Care Investment
SV Life Sciences notes that SV Life Science fund V invested in U.S. Renal Care, dialysis service to patients with end stage renal disease (ESRD) as part of a $20m series financing round.  ...

Read more

Team - Tom Flynn, Eugene Hill
May 2012
US Renal Care - Exit
SV Life Sciences notes that US Renal Care completed a $137m Dividend Recapitalization, which required increasing Senior Debt from $131m to $215m and increasing Mezzanine Debt from $40.5m to $100m.  ...

Read more

Team - Eugene Hill
May 2012
Patient Care Exit
SV Life Sciences notes that in May 2010 – Almost Family (Nasdaq: AFAM) entered into a definitive agreement to acquire all stock of Patient Care. The total purchase price for the stock is $45.2m, subject to a working capital adjustment ...

Read more

Team - Eugene Hill

⇧ Back to top